Disease landscape
Leukemia (AML)
Significant constraints in access to AML diagnosis and treatment have been identified in the Visegrád (V4) countries. The obtained scores place the indicator for AML at a medium level among all assessed diseases. Results vary significantly from state to state - the difference between the highest and the lowest score exceeds 31 points. The main reason for the unsatisfactory performance of the V4 group in AML is limited access to novel drugs in all the V4 countries due to the lack of reimbursement or strict reimbursement criteria. Despite these limitations of systemic reimbursement for all included drugs for AML patients, the proportion of patients treated with a subset of selected drugs in the Czech Republic and Slovakia is very high. The area that pulls the total score up in all countries is the relatively good access to AML diagnosis in the region and relatively decent time to availability (compared to other diseases).
Cross-Country
General GAP for AML
Compliance with guidelines
Positive recommendations for 6 AML drugs were found in analyzed clinical practice guidelines. Between 3 and 5 of these are available for AML patients in the individual V4 countries.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
Selected drugs
Drug access
Number of patients treated (2022)
Drug access
POPULATION treated - selected drugs (%)*
*percentage of the population potentially eligible for treatment with selected drugs: Rydapt, Venclyxto, Xospata.
Main issues
- The average time to reimbursement for AML drugs in the V4 countries is 2.8 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 1.2 years.
- The uptake of selected novel drugs in a target population is highly differentiated and ranges from about 20% in Hungary and Poland and more than 80% in Slovakia and Czechia.
- DALY (disability adjusted life-years) burden related to AML in the V4 countries is lower (up to 10%) than the European Union average.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).